Patented Medicine Prices Review Board

Patented Medicine Prices Review Board

April 29, 2009 16:35 ET

The Patented Medicine Prices Review Board Approves a Voluntary Compliance Undertaking for the Medicine Concerta

OTTAWA, ONTARIO--(Marketwire - April 29, 2009) - The Board issued a Notice of Hearing pertaining to allegations of Board Staff that Concerta had been, and was being, sold by Janssen-Ortho Inc. at prices exceeding those indicated by the Board's Excessive Price Guidelines. On April 3, 2009, the Hearing Panel received a Voluntary Compliance Undertaking ("VCU") which proposed to resolve the issues raised in the Notice of Hearing.

The VCU requires, among other things, that Janssen-Ortho offset excess revenues in the amount of $1,464,441.58 by making a payment to the Government of Canada. By Order of the Board, the proceeding into the price of Concerta is hereby concluded.

The Board Order is a public document and is available on the PMPRB Web site, along with the VCU, under Regulatory; Hearings; Concerta, and under Voluntary Compliance Undertakings.

Concerta is indicated for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD")

Contact Information